Show simple item record

dc.creatorStojanović, Marijana
dc.creatorLukić, Ivana
dc.creatorMarinković, Emilija
dc.creatorKovačević, Ana
dc.creatorMiljković, Radmila
dc.creatorTobias, Joshua
dc.creatorSchabussova, Irma
dc.creatorZlatović, Mario
dc.creatorBarisani-Asenbauer, Talin
dc.creatorWiedermann, Ursula
dc.creatorInic-Kanada, Aleksandra
dc.date.accessioned2020-12-13T21:34:56Z
dc.date.available2020-12-13T21:34:56Z
dc.date.issued2020
dc.identifier.issn2076-393X
dc.identifier.urihttp://cherry.chem.bg.ac.rs/handle/123456789/4292
dc.description.abstractVaccines can have heterologous effects on the immune system, i.e., effects other than triggering an immune response against the disease targeted by the vaccine. We investigated whether monoclonal antibodies (mAbs) specific for tetanus could cross-react with Chlamydia and confer heterologous protection against chlamydial infection. The capability of two tetanus-specific mAbs, namely mAb26 and mAb51, to prevent chlamydial infection has been assessed: (i) in vitro, by performing a neutralization assay using human conjunctival epithelial (HCjE) cells infected with Chlamydia trachomatis serovar B, and (ii) in vivo, by using a guinea pig model of Chlamydiacaviae-induced inclusion conjunctivitis. The mAb26 has been superior in comparison with mAb51 in the prevention of chlamydial infection in HCjE cells. The mAb26 has conferred ≈40% inhibition of the infection, compared to less than 5% inhibition in the presence of the mAb51. In vivo, mAb26 significantly diminished ocular pathology intensity in guinea pigs infected with C. caviae compared to either the mAb51-treated or sham-treated guinea pigs. Our data provide insights that tetanus immunization generates antibodies which induce heterologous chlamydial immunity and promote protection beyond the intended target pathogen.
dc.languageen
dc.relationThis work was institutionally funded by the Institute for Specific Prophylaxis and Tropical Medicine, Medical University of Vienna, Austria, and partially supported by the Austrian Research Promotion Agency (FFG project number 822768).
dc.relationinfo:eu-repo/grantAgreement/MESTD/inst-2020/200177/RS//
dc.relationinfo:eu-repo/grantAgreement/MESTD/inst-2020/200168/RS//
dc.rightsopenAccess
dc.sourceVaccines
dc.subjectantibodies
dc.subjectChlamydia
dc.subjectcross-reactivity
dc.subjectheterologous immunity
dc.subjecttetanus
dc.subjectvaccination
dc.titleCross-Reactive Effects of Vaccines: Heterologous Immunity between Tetanus and Chlamydia
dc.typearticleen
dc.rights.licenseBY
dcterms.abstractЛукић, Ивана; Маринковић, Емилија; Барисани-Aсенбауер, Талин; Тобиас, Јосхуа; Златовић, Марио; Стојановић, Маријана; Ковачевић, Aна; Миљковић, Радмила; Сцхабуссова, Ирма; Wиедерманн, Урсула; Иниц-Канада, Aлександра;
dc.citation.volume8
dc.citation.issue4
dc.citation.spage719
dc.identifier.wos000601709900001
dc.identifier.doi10.3390/vaccines8040719
dc.citation.rankM21~
dc.type.versionpublishedVersion
dc.identifier.scopus2-s2.0-85097255732
dc.identifier.fulltexthttp://cherry.chem.bg.ac.rs/bitstream/id/26455/Cross-Reactive_Effects_pub_2020.pdf


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record